Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
<h4>Background</h4>Identifying predictive biomarkers of drug response is of key importance to improve therapy management and drug selection in cancer therapy. To date, the influence of drug exposure and pharmacogenetic variants on sorafenib-induced toxicity remains poorly documented. The...
Guardado en:
Autores principales: | Pascaline Boudou-Rouquette, Céline Narjoz, Jean Louis Golmard, Audrey Thomas-Schoemann, Olivier Mir, Fabrice Taieb, Jean-Philippe Durand, Romain Coriat, Alain Dauphin, Michel Vidal, Michel Tod, Marie-Anne Loriot, François Goldwasser, Benoit Blanchet |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/80507bd316a74a50b6e32edbe689dc73 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
por: Olivier Mir, et al.
Publicado: (2012) -
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
por: Romain Coriat, et al.
Publicado: (2011) -
Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
por: Javier Aubán-Pariente, et al.
Publicado: (2021) -
Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Junji Furuse
Publicado: (2008) -
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
por: Coriat R, et al.
Publicado: (2016)